Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RANITIDINE HCL

All products: general benefit

Other products in the same Health Canada class (A02B, A02BA) — coverage varies; not interchangeable

  • Cimetidine (Cimetidine): general benefit, Not a benefit
  • Famotidine (Pepcid): general benefit, Not a benefit
  • Nizatidine (Axid): general benefit
  • Misoprostol (Cytotec): general benefit, Not a benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

Teva-Ranitidine Solution · DIN 02242940 · 15mg/mL · Oral Sol

General benefit; Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.Discontinued 2020-06-10 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ranitidine Solution · DIN 02242940 Manufacturer: Teva Canada Limited; listing date 2004-12-21 Health Canada: Cancelled post market since 2020-06-10 · brand TEVA-RANITIDINE SOLUTION · ATC A02BA02 RANITIDINE · form Solution · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 75 MG/5ML · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ranitidine Solution: Formulary list price $0.1480/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1480 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66779 · Verify on the e-Formulary ↗ (DIN 02242940)

Source record
DIN 02242940: Teva-Ranitidine Solution Raw flags: sec3=Y Item: 564000038; group id 697; item number 1721; lccId None; manufacturer id TEV Source form: Oral Sol; strength: 15mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1480; ministry $0.1480 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242940 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66779
Interchangeable products
Apo-Ranitidine · DIN 02280833 · $0.1480 Zantac · DIN 02212374 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE MAR-RANITIDINE (ranitidine hydrochloride) Tablets are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the following:  The treatment of nonsteroidal anti-inflammatory drug (NSAID) – induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;  The prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;  The prophylaxis of recurrent hemorrhage from bleeding ulcers;  The prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, MAR-RANITIDINE is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. https://pdf.hres.ca/dpd_pm/00034672.PDF PM date: not printed or not captured Source product: MAR-RANITIDINE; DIN 02443708; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.